

CMBI Credit Commentary

CHFOTN: Thoughts on the debt restructuring plan

8-yr extension, up to 70% debt to trust/equity swap....

In brief, the debt restructuring plan is to swap up to 70% of its debt into trust units/equities or extend maturity of CFLD's "eligible redemption debts" of RMB134bn for 8-year, and the remaining 30% will be settled with proceeds from asset disposals. The eligible redemption debts include 11 offshore bonds with total outstanding amount of USD4.96bn (cRMB35bn) and other onshore debts. CFLD will earmark an asset portfolio with NAV of RMB50mn, c30% of eligible redemption debts of RMB134bn. CFLD is yet to identify the disposable assets and hence, we do not have sufficient information to gauge the fair value of disposable assets. Please see the Appendix 1 for details of the restructuring plan.

.... cash redemption by Dec'23 on a best effort basis....

As per the debt restructuring plan, CFLD will sell assets in disposable portfolio and, on a best effort basis, to redeem 64.2% of Bond 1 in cash, i.e. c30% cash repayment (including 1% cash prepayment fee to be paid on restructuring effect date) by 31 Dec'23. Failure to Bond 1 in cash by 31 Dec'23 is not an event of default.

.... 1% cash prepayment fee to be deducted from principal amount

In our view, the cash pre-payment fee is more of a principal repayment as the "fee" will be deducted from the principal amount. The cash prepayment fee deadline is on 13 Oct'22 and the longstop date of the restructuring plan is 31 Mar'23.

Bond 2 or Bond 3?

We do not have sufficient information on the 3 companies to gauge whether the equity valuation of RMB50bn by 2026 is fair! There will be no investors' put on Bond 2 if these businesses will not be IPOed by 2026.

Another noteworthy point is that there is no cap on holders to pick Bond 2. Assuming creditors of all the remaining 53.3% eligible redemption debts, i.e. RMB71.4bn, pick Bond 2, the attributable value of the equities will only be sufficient to cover c35% of Bond 2 before the 33% premium to incentivize holders to pick Bond 2. Recalled that holders of Bond 2 will have a maximum of 50% interests in the 3 companies, hence valuation attributable to Bond 2 holders will be capped at RMB25bn based on the valuation of CFLD.

Glenn Ko, CFA 高志和
(852) 3657 6235
glennko@cmbi.com.hk

Cyrena Ng, CPA 吳蒨瑩
(852) 3900 0801
cyrenang@cmbi.com.hk

CMBI Fixed Income
fis@cmbi.com.hk

Will Bond 3 offer more uncertainties? We are not sure! We expect that CFLD have to carve out the more liquid and higher quality assets as credit enhancements for Bond 1 and Bond 2. If so, there will be quite a bit of uncertainties in term of the sources of repayment for Bond 3 after 8 years.

What are the approval thresholds?

CFLD and its advisor are yet to decide if the restructuring will be in the form of consent or scheme, pending on the investors' response. For consent, the restructuring of each individual USD bonds is not dependent on the consent of other bonds. Theoretically, CFLD can restructure some instead of all USD bonds. The approval thresholds are a quorum of at least 2/3 in principal amount and at least 2/3 in principal amount of the quorum vote for the restructuring proposal.

For scheme, the approval will be on an aggregate basis for the 11 outstanding USD bonds. The approval thresholds are at least 75% in principal amount and at least 50% headcount in the creditors' meeting. There will be no minimum principal amount requirement in the scheme meeting.

Ad-hoc group claims to have secured veto


The ad-hoc group claimed in the call last evening that it held over 25% of the aggregate amount CFLD's USD bonds, and a veto of the restructuring plan. The group mentioned its opposition to the existing restructuring plan, and preparation for winding-up petitions in Hong Kong.

Fair value estimates at 16-51 per 100

Purely for the sake of discussions, we estimate the fair value of CHFOTNs to be 16-51. We assume that CFLD can divest the disposable asset portfolio by end of 2023 and monetize the trust by end of 8th year but apply discount rates of 0-50% to the asset value provided by the company. For the equities, we assume that investors can monetize them by end of 2026, again, we apply discount rates of 0-50% to the valuation of RMB50bn provided by the company various. A caveat is not all creditors can pick 100% Bond 2 as discussed previously.

Discount to asset/equity values provide by	CFLD	Discount rate		
		30%	35%	40%
0%	Bond 1/Bond 2	50.7	45.8	41.7
	Bond 1/Bond 3	33.4	30.0	27.4
30%	Bond 1/Bond 2	35.9	32.4	29.5
	Bond 1/Bond 3	26.0	23	20.8
50%	Bond 1/Bond 2	26.0	23.5	21.4
	Bond 1/Bond 3	21.1	18.4	16.3

Appendix 1: Summary of debt restructuring plan



CMB International Global Markets Limited

Fixed Income Department

Tel: 852 3761 8867/ 852 3657 6291

fis@cmbi.com.hk

CMB International Global Markets Limited ("CMBGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclaimer:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.